Concise Prescribing Info
Type 2 diabetes, in cases where dietary measures have failed.
Dosage/Direction for Use
Adult <65 yr Initially 1 tab/day. Adjust dose depending on the blood glucose response & in steps of 1 tab at a time (at least 14 days should separate successive steps in the dose). Maintenance: 1-4 tab/day. Usual dose: 2 tab/day. >65 yr Initially ½ tab once daily, increase accordingly while keeping to steps of at least 14 days between successive levels & w/ close monitoring of blood glucose.
Should be taken with food: Take w/ meals to minimize GI disturbances.
Hypersensitivity to gliclazide, other sulfonylureas or sulfonamides. Type 1 diabetes; diabetic pre-coma & coma, diabetic ketoacidosis. Concomitant use w/ miconazole. Severe renal or hepatic insufficiency. Lactation.
Special Precautions
Hypoglycemia. Malnutrition, irregular mealtimes, skipping meals, periods of fasting or dietary changes; imbalance between physical exercise & carbohydrate intake. Thyroid disorders, hypopituitarism & adrenal insufficiency. St. John's wort prep, fever, injury, infection or surgery may affect blood glucose control. Dysglycemia (concomitant use w/ fluoroquinolones, especially in elderly). Monitor blood glucose regularly. G6PD-deficiency. Contains lactose. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May impair ability to drive or operate machinery. Avoid use during pregnancy. Elderly.
Adverse Reactions
Hypoglycemia, sweating, clammy skin, anxiety, tachycardia, HTN, palpitations, angina pectoris & cardiac arrhythmia. Abdominal pain, nausea, vomiting, dyspepsia, diarrhea & constipation. Rash, pruritus, urticaria, angioedema, erythema, maculopapular rashes, bullous reactions (eg, Stevens-Johnson syndrome & toxic epidermal necrolysis), & exceptionally, drug rash w/ eosinophilia & systemic symptoms (DRESS); raised hepatic enzyme levels (AST, ALT, alkaline phosphatase), hepatitis; transient visual disturbances.
Drug Interactions
Increased hypoglycemia w/ miconazole (systemic route, oromucosal gel); phenylbutazone (systemic route); alcoholic drinks & any medicinal products containing alcohol (antabuse effect). Potentiate blood glucose lowering effect w/ other antidiabetic agents (insulin, acarbose, metformin, thiazolidinediones, dipeptidylpeptidase-4 inhibitors, GLP-1 receptor agonists), β-blockers, fluconazole, ACE inhibitors (captopril, enalapril), H2-receptor antagonists, MAOIs, sulfonamides, clarithromycin & NSAIDs. Diabetogenic effect of danazol. Increased blood glucose levels (reduced insulin release) w/ chlorpromazine (>100 mg/day); w/ possible ketosis (reduced carbohydrates tolerance) w/ glucocorticoids (systemic & local route, IA, cutaneous & rectal prep) & tetracosactide; due to β2-agonist effects w/ ritodrine, salbutamol, terbutaline (IV route). Decreased exposure w/ St. John's wort (Hypericum perforatum). Dysglycemia w/ fluoroquinolones. Potentiation of anticoagulant therapy (warfarin).
MIMS Class
ATC Classification
A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.
Diamicron tab 80 mg
100's (P812.5/box);60's (P487.5/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in